Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 854

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 854
---
atus”), Liminatus Pharma Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of ParentCo (“Liminatus Merger Sub”), and SPAC Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of ParentCo (“SPAC Merger Sub”), which provides, among other things, that (i) Liminatus Merger Sub will merge with and into Liminatus (the “Liminatus Merger”), with Liminatus surviving the Liminatus Merger as a direct wholly-owned subsidiary of ParentCo, and (ii) simultaneously with the Liminatus Merger, SPAC Merger Sub will merge with and into Iris (the “SPAC Merger” and, together with the Liminatus Merger, the “Mergers”), with Iris surviving the SPAC Merger (the “SPAC Surviving

TABLE OF CONTENTS

2approve the Business Combination, as described in more detail in the attached proxy statement/prospectus.(2)The Nasdaq Proposal – To approve, as required by the rules of the Nasdaq Stock Market LLC, the issuance of ParentCo Common Stock in the Business Combination (including the PIPE Investor’s commitment to purchase 2,500,000 shares of ParentCo Common Stock at a purchase price per share of $10.00, for an aggregate purchase price of $25,000,000) in an amount greater than 20% of the number of shares of Iris common stock before such issuance.FOR☐AGAINST☐ABSTAIN☐(3)The Incentive Plan Proposal – To approve and adopt the ParentCo 2024 Omnibus Equity Incentive Plan.FOR☐AGAINST☐ABSTAIN☐(4)The ParentCo Charter Proposal – To approve, on an advisory and non-binding basis, the ParentCo’s amended and restated certificate of incorporation (the “ParentCo Certificate of Incorporation”), to be approved and adopted in connection with the Business Combination.FOR☐AGAINST☐ABSTAIN☐(5)Advisory Charter Proposals – To consider and vote, on an advisory and non-binding basis, on the following proposals 5A, 5B, 5C, 5D, 5E and 5F, to approve certain governance provisions in the proposed ParentCo Certificate of Incorporation.(5A)Advisory Charter Proposal 5A — To amend the name of the public entity to “Liminatus Pharma,